August 25, 2017 09:11 AM EDTUpdated 09:25 AM

Novartis’ Kisqali to go head-to-head with Pfizer’s Ibrance; USC joins regional biotech alliance

Shehla Shakoor

Managing Director

⇨ Novartis said on Thursday that Kisqali (ribociclib) had been OK’d by EU regulators for frontline breast cancer, setting up a direct rivalry with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis’ Kisqali to go head-to-head with Pfizer’s Ibrance; USC joins regional biotech alliance

Shehla Shakoor

Managing Director

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Sofinnova outlines $550M fund after IPOs and M&A deals

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

No­var­tis’ Kisqali to go head-to-head with Pfiz­er’s Ibrance; USC joins re­gion­al biotech al­liance

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Novartis’ Kisqali to go head-to-head with Pfizer’s Ibrance; USC joins regional biotech alliance

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Sofinnova outlines $550M fund after IPOs and M&A deals

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena